<?xml version="1.0"?>
<Articles JournalTitle="Acta Medica Iranica">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>53</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="epublish">
        <Year>2015</Year>
        <Month>11</Month>
        <Day>29</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">The Comparison of WHOQOL-BREF with Disease Specific Heath Related Quality of Life Questionnaire in Irritable Bowel Syndrome</title>
    <FirstPage>717</FirstPage>
    <LastPage>724</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Raika</FirstName>
        <LastName>Jamali</LastName>
        <affiliation locale="en_US">Research Development Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammad</FirstName>
        <LastName>Biglari</LastName>
        <affiliation locale="en_US">Department of Internal Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>11</Month>
        <Day>29</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Irritable Bowel Syndrome (IBS) is one of the most common gastrointestinal disorders particularly affecting the quality of life (QOL). Evaluating QOL in IBS patients is a valuable method of defining a psychobiological pattern of disease. Various disease specific and general instruments are now available to measure health-related QOL (HRQOL) in IBS patients. Though, no comparison has been made between these tools especially in non-western countries. We aimed to compare QOL measures between two specific and general QOL questionnaires in a sample of Iranian IBS patients. A total of 250 IBS patients were diagnosed based on Rome III criteria (mean age 29.6 &#xB1; 9.6 years). HRQOL was assessed using disease specific quality of life for IBS (IBS-QOL) and generic World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaires. Patients also completed Speilberger`s &#x201C;State/Trait Anxiety Inventory&#x201D; and &#x201C;Beck Depression Inventory-II&#x201D; for the evaluation of anxiety and depression symptoms. The severity of symptoms was independently associated with HRQOL in patients using WHOQOL-BREF and IBS-QOL (r = -0.48 and -0.39 respectively, P &lt; 0.001). In linear regression analysis, a strong correlation was observed between the HRQOL scores of IBS-QOL and the WHOQOL-BREF questionnaires (standard &#x3B2; = 0.86 (95%CI: 1.15 - 1.44), P value &lt; 0.001). Controlling for anxiety and depression symptoms did not influence the strength of observed correlation. The WHOQOL-BREF is a psychometrically sound, rapid and convenient instrument whose HRQOL measure is as valid and accurate as the disease-specific IBS-QOL questionnaire. It seems reasonable to use the WHOQOL-BREF alongside the IBS-QOL.</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/5217</web_url>
    <pdf_url>https://acta.tums.ac.ir/index.php/acta/article/download/5217/4718</pdf_url>
  </Article>
</Articles>
